Advanced Technology Radiation Therapy Clinical Trials Support (ATC) (Limited Competition U24)

The summary for the Advanced Technology Radiation Therapy Clinical Trials Support (ATC) (Limited Competition U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Advanced Technology Radiation Therapy Clinical Trials Support (ATC) (Limited Competition U24): The overall purpose of this Funding Opportunity Announcement (FOA) is to facilitate and support clinical trials that employ advanced technology radiotherapy methods, particularly those requiring digital data submission. To further this goal, the National Cancer Institute (NCI) intends to continue funding for the Advanced Technology Radiation Therapy Clinical Trials Support (ATC) consortium, which was created as a result of RFA-CA-98-006 and continued under RFA-CA-02-505.

Federal Grant Title:	Advanced Technology Radiation Therapy Clinical Trials Support (ATC) (Limited Competition U24)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-07-503
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Cancer Treatment Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Dec 01, 2006
Posted Date:	Oct 16, 2006
Creation Date:	Oct 17, 2006
Archive Date:	Dec 31, 2006
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	1
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Foreign institutions are not eligible to apply. Eligible institutions will be restricted to current ATC awardees due to the necessity to preserve and extend the existing infrastructure.The initial 8-year award period has seen the development of an infrastructure which could not be transferred to a different awardee without significant loss of resources and interruption of support for existing and proposed clinical trials protocols. These resources include hardware, software, staff and processes.While the NCI recognizes and endorses the need for full and open competition and, by preference, utilizes open competition for most initiatives, this instance is an exception. It is clear to the Institute that the transfer of the high technology quality assurance program to a new awardee would hamper the ongoing efforts of several of the clinical trials groups as they attempt to utilize more aggressive, high-technology radiation methods in single and combined modality trials.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...